Chief Scientific Officer, Vice President Drug Discovery, And Ceo Of The Oncology Subsidiary
Celle L'Evescault, Nouvelle Aquitaine - Vienne, Fr
Created in 1990, listed on NYSE Euronext, Cerep has been a leader in Drug Discovery services, combining an original business model of profitable services with drug discovery. With a center for in vitro pharmacology and drug profiling in Poitiers (France), one dedicated to ADMET in Seattle (Wash.), to combinatorial and medicinal chemistry as well as in vivo pharmacology in Rueil (France), a subsidiary dedicated to clinical services (Allschwil, Switzerland), and a subsidiary dedicated to oncology research, Cerep has employed up to 500 employees. It has counted up to 400 clients on a yearly basis, as well as a portfolio of drugs at preclinical and clinical stages either from internal research or in the framework of strategic collaborations in the fields of Oncology, Obesity, Immuno-Inflammation, Thrombosis. Cerep was acquired by Eurofins in 2013.